Topotecan HCl

Catalog No.S1231 Synonyms: NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl Chemical Structure

Molecular Weight(MW): 457.91

Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 180 In stock
USD 320 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Topotecan HCl is a topoisomerase I inhibitor for MCF-7 Luc cells and DU-145 Luc cells with IC50 of 13 nM and 2 nM in cell-free assays, respectively.
Features Topotecan is a water-soluble derivative of camptothecin.
Targets
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
In vitro

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells Mn7NR5l1d3SxeHnjxsBie3OjeR?= NX\aUWFEPzJiaB?= NUHsUox{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBq[zVyPUGgcm0> NHrJUmUzODN5MUG4Ny=>
human Bel7402 cells NIL4SGNEgXSxdH;4bYPDqGG|c3H5 MmHqPVYhcA>? MlXQR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRoVtPzRyMjDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOiCwTR?= MojUNVUyPjVzNES=
human HCT8 cells NFfGWIxEgXSxdH;4bYPDqGG|c3H5 MmDqPVYhcA>? MW\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT61JI5O MXuxOVE3PTF2NB?=
human MCF7 cells NWTadoJDS3m2b4TvfIlkyqCjc4PhfS=> M2S3b|k3KGh? MlfYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC5OkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuPEBvVQ>? M4fVZ|E2OTZ3MUS0
human A549 cells NVrKUJFTS3m2b4TvfIlkyqCjc4PhfS=> NFnkb4g6PiCq NFnGU5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9N{4zKG6P NIXqd5UyPTF4NUG0OC=>
human colon carcinoma SW620 cell NEf1OJlEgXSxdH;4bYPDqGG|c3H5 NFnVZ5pEgXSxdH;4bYMheG:2ZX70bYF1cW:wIH;mJHRweG:2ZXPhckApXFBrIHL5JJRp\SClb33wc5Vv\CCrbjDoeY1idiClb3zvckBk[XKlaX7vcYEhW1d4MkCgZ4VtdCCuaX7lMEBKSzVyPUOuNkBvVQ>? NYLaTWFQOTJ2MEi3NFc>
human MESSA cells NHv0TFZEgXSxdH;4bYPDqGG|c3H5 MXK3NkBp M{fjcmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GW1ODIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME20JI5O NEnXVG8zOTN2MU[3OC=>
human BGC823 cells M1qyVGN6fG:2b4jpZ:Kh[XO|YYm= MWi5OkBp MmLTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRmdEQDJ|IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE4{KG6P NYC0VYJSOTVzNkWxOFQ>
human Ketr3 cells NWfFcJJTS3m2b4TvfIlkyqCjc4PhfS=> NYToTWFTQTZiaB?= MkCwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT4V1ejNiY3XscJMh[W[2ZYKgPVYhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20Mlkhdk1? MWmxOVE3PTF2NB?=
LOX cells MoLaR5l1d3SxeHnjxsBie3OjeR?= M3G1cGN6fG:2b4jpZ4l1gSC5YYOg[IV1\XKvaX7l[EBqdiC4aYTyc{BqdiCOT2igZ4VtdHNiKH3lcIFvd22jKTDv[kBpfW2jbjD0eY1weiClZXzsJIxqdmW|IHL5JJV{cW6pIF3UWEBie3OjeTygTWM2OD13IH7N Mn7OO|g2OzN|MR?=
human A549 cells MX7GeY5kfGmxbjDhd5NigQ>? MofsOEBp NFjzcGdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IESgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD13IH7N M1rpd|E5OjB5N{S4
human H69 cells Ml23R5l1d3SxeHnjxsBie3OjeR?= NY\rdYU5PzJiaB?= MYTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LDDJR|UxRTZibl2= MVuyNVM1OTZ5NB?=
human A2780 cells M3jnWWN6fG:2b4jpZ:Kh[XO|YYm= MUK3NkBp MY\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> NV60NY85OjJ7NUmyOFY>
human LNCAP cells MofsR5l1d3SxeHnjxsBie3OjeR?= MnniO|IhcA>? M33zOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME25JI5O M4rEZ|IyOzRzNke0
human HOP62 cells M2PKbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzzS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTG9RPjJiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P M{S5XFI2QTB7Mke5
human MCF7 cells MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGXXNlVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGK7IH\peoUu\G:|ZTDndo94fGhiaX7obYJqfGmxbjDhd5NigSxiSVO1NF0yOCCwTR?= MXGyOVkxQTJ5OR?=
human UACC62 cells NIXr[IJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIKzN3RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBWSUOFNkKgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N MXqyOVkxQTJ5OR?=
human DU145 cells NVzuOopbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVuy[2hDT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hTFVzNEWgZ4VtdHNiYomg[ol3\S2mb4PlJIdzd3e2aDDpcohq[mm2aX;uJIF{e2G7LDDJR|UxRTFyIH7N NFzjdHczPTlyOUK3PS=>
LoVo cell line MX7DfZRwfG:6aXRCpIF{e2G7 NEjGbVBEgXSxdH;4bYMheG:2ZX70bYF1cW:wIH;mJHRweG:2ZXPhckApXFBrIHL5JJRp\SClb33wc5Vv\CCrbjCobJVu[W5iY3;sc5Jm[3SjbDDjZY5k\XJiTH;Wc{Bk\WyuIHzpcoUtKEmFNUC9NVEvPiCwTR?= MlfINVI1ODh5MEe=
human lymphoblast tumor cell line RPM18402 NGLBU25EgXSxdH;4bYPDqGG|c3H5 NIfIWlNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtgW2yaH;icIF{fCC2dX3vdkBk\WyuIHzpcoUhWlCPMUi0NFItKEmFNUC9NVIhdk1? NGL5fVEyOjN7Mke0OS=>
human HL60 cells M3fDT2Z2dmO2aX;uJIF{e2G7 MXLBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKTE[wJINmdGy|IHL5JHNTSiCvZYToc4QtKEmFNUC9NVIhdk1? NIfH[W4yQTV2MUS4Ny=>
human A375 cells M3;WeWN6fG:2b4jpZ:Kh[XO|YYm= NY\0b4pvPzJiaB?= NUnteVQzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTN5NTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NVMhdk1? MlS3NlE{PDF4N{S=
COR-L23/P cell NWXOe5NGS3m2b4TvfIlkyqCjc4PhfS=> NV7DcnZES3m2b4TvfIlkcXS7IH3lZZN2emWmIIXzbY5oKHSqZTDDU3IuVDJ|IIDhdoVvfGGuIDjDU3IuVDJ|L2CpJIh2dWGwIH7vckB{dWGubDDj[YxtKGy3bnegZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2xN{4zKG6P NIK2V3YyOThyNkeyOC=>
human NCI-H460 cells NVvzNWZYWHKxbHnm[ZJifGmxbjDhd5NigQ>? MUK3NkBp MmT6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N MUmyNVc5OzN4OR?=
human MOLT4 cells NFXSVJBEgXSxdH;4bYPDqGG|c3H5 NFHE[XA4OiCq MYXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUG5JI5O Mo\KNlQ6ODB5MkW=
human LoVo cells MYDDfZRwfG:6aXRCpIF{e2G7 NYPQ[W5NPzJiaB?= Mke5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUI9XdyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUKwJI5O MVeyNFM4OTF6Mx?=
RPM18402 tumor cell line NGnySHBRem:uaX\ldoF1cW:wIHHzd4F6 NVPaS5hoS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JINmdGxicILvcIln\XKjdHnvckBqdiCUUF2xPFQxOiC2dX3vdkBk\WyuIHzpcoUtKEmFNUC9NlAhdk1? MWmxOVQ5Ojl{OR?=
human SN12C cells NITTUnlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MorZS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P M4rIVFI2QTB7Mke5
human RPMI8226 cells MmPQR5l1d3SxeHnjxsBie3OjeR?= NFvNNWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWE2LOEKyOkBk\WyuczDifUBOXFRibXX0bI9lNCCLQ{WwQVIyKG6P NHuzTZcyQTBzMkm5Oi=>
HT-29 cells M2HtbGN6fG:2b4jpZ:Kh[XO|YYm= MlnZR5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEiWLUK5JINmdGy|KHPvcI9vMSCxZjDoeY1idiC2dX3vdkBk\WyuIHzpcoV{KGK7IIXzbY5oKE2WVDDhd5NigSxiSVO1NF0zPSCwTR?= NIDEVFM4QDV|M{Ox
SK-BR-3 cells NYLUcIc1S3m2b4TvfIlkyqCjc4PhfS=> MVfJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHygcIlv\SBqU1utRnIuOyluIFnDOVA:OjZibl2= M4Lr[VEyOzN2NU[5
HeLa cells M1nMN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NETBeXlIem:5dHigbY5pcWKrdHnvckBw\iCKZVzhJINmdGy|IHHmeIVzKDRiZHH5d{whT0l3ME2zNEBvVQ>? NYTwUY1mOTd2MUi1PFI>
UACC 62 cells MXPDfZRwfG:6aXRCpIF{e2G7 MYHU[ZN1\WRiaX6geol1em9iZn;yJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJR2dW:{IHPlcIwhdGmwZTDVRWNEKDZ{IDjt[Yxidm:vYTmsJGdKPTB;M{Cgcm0> NFn4PJEyODdzNEWwNi=>
human HCT116 cells MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1;aTWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFfJOVA:OzBibl2= NF;QWYEzPTlyOUK3PS=>
human lung cancer cell line (H128) NF7SV5VEgXSxdH;4bYPDqGG|c3H5 Mn;wTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiKMUK4LUwhUUN3ME2zNUBvVQ>? NIHZcoIyOTN|NEW2PS=>
human MES-SA/Dx5 cells Mmj4R5l1d3SxeHnjxsBie3OjeR?= NV\yVJAyS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2zN{BvVQ>? NVnGXGd1OjF|NEG2O|Q>
human A2780 cells MXHDfZRwfG:6aXRCpIF{e2G7 MXW3NkBp M3PzRWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N|Mhdk1? MlfVNlQ6ODB5MkW=
human MDA-MB-435 cells MX7DfZRwfG:6aXRCpIF{e2G7 MkLRO|IhcA>? MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNEO1JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPzJiaILzJIJ6KE2WVDDhd5NigSxiR1m1NF0{PCCwTR?= NYrWZoVjOjJ6NkewNVk>
human stomach cancer cell line (MKN45) MnqwR5l1d3SxeHnjxsBie3OjeR?= M3fTe2lvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR|UxRTN6IH7N M4fXeVEyOzN2NU[5
human KB3-1 cells M17HRmN6fG:2b4jpZ:Kh[XO|YYm= MnrqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gT2I{NTFiY3XscJMh[W[2ZYKgUXRVKGG|c3H5MEBKSzVyPUSwJI5O M1zuUVE5QDJ7M{O0
mouse P388 cells NYfSVox{S3m2b4TvfIlkyqCjc4PhfS=> MlPNR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgVFM5QCClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NEWgcm0> MUSxPFgzQTN|NB?=
A427 human lung carcinoma NXXyb3JMWHKxbHnm[ZJifGmxbjDhd5NigQ>? MkTSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgcYVie3W{ZXSgZYdicW6|dDDBOFI4KGi3bXHuJIx2dmdiY3HyZ4lvd22jLDDJR|UxRTR7IH7N MW[5PFc3OTFz
human U251 cells MYDGeY5kfGmxbjDhd5NigQ>? MWi2MVI1KGh? MVHJcohq[mm2aX;uJI9nKHSxcH;pd49u\XKjc3WtNUBqdiCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHnuJI52[2ynYYKg[Zh1emGldDDh[pRmeiB4IITvJFI1KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{NCCHQ{WwQVU1KG6P NIDYXZAzOjNyNU[xNi=>
human colon cancer cell line (WiDr) NX3TOnM1S3m2b4TvfIlkyqCjc4PhfS=> Mm\STY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9OVYhdk1? M2O4dVEyOzN2NU[5
human HepG2 cells M1;DZWN6fG:2b4jpZ:Kh[XO|YYm= NEHONZQ1KGSjeYO= M2XoPWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGGodHXyJFQh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9OlAhdk1? M{KxUlE5PTV2OUC2
human KB cells M{m5bGN6fG:2b4jpZ:Kh[XO|YYm= MofaO|IhcA>? NECwTYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSiClZXzsd{Bi\nSncjC3NkBpenNic4Xs[o9zcG:mYX3pcoUhSiClb3zvdolu\XS{aXOgZZN{[XluIFnDOVA:PjJwNTDuUS=> MV6yOVAxQDR3Nh?=
human HCT8 cells NHLBTllEgXSxdH;4bYPDqGG|c3H5 MV:zJIRigXN? NEDT[ZpEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1? MVOyNFM6OjV2NR?=
human GBM2 cells M3nKdnBzd2yrZnXyZZRqd25iYYPzZZk> M3G3elczKGh? M1W3eWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvOTNizszN NInpWZEzPjN3NUWzNi=>
SK-MEL-2 cells M4XyTGN6fG:2b4jpZ:Kh[XO|YYm= MUW3NkBp MWfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1OTUxvMjDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZktKEmFNUC9NE4yPCEQvF2= MWeyNVM1OTZ5NB?=
human IGROV1 cells Moj2R5l1d3SxeHnjxsBie3OjeR?= MYW3NkBp MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyPUCuNVYh|ryP MX6yNVM1OTZ5NB?=
human U87 cells NEHrZYhRem:uaX\ldoF1cW:wIHHzd4F6 M{nUO|Q5KGh? Ml;aRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCXOEegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkG2JO69VQ>? MUSyOFgzPjhzOB?=
human HT1080 cells NVjtTmVGWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3jaXVQ5KGh? M4XlbGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> MofxNlY1ODh6MUW=
human Hep3B cells MVvQdo9tcW[ncnH0bY9vKGG|c3H5 NYP1bIlLPzJiaB?= NIXjPGVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmsJGdKPTB;MD6yNkDPxE1? MXWxPVc6Pjl3Nh?=
human GBM3 cells MmHIVJJwdGmoZYLheIlwdiCjc4PhfS=> MojwO|IhcA>? M2mwOGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iR1LNN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgW3NVNTFibXX0bI9lNCCLQ{WwQVAvOzhizszN NHTQOpgzPjN3NUWzNi=>
human KBVIN cells NW\ZNWpES3m2b4TvfIlkyqCjc4PhfS=> MUi3NkBp M{izXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDXkmQIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUC9NE41KM7:TR?= NHfudYIzPTR|OEe2PS=>
human GBM1 cells NI\FVXhRem:uaX\ldoF1cW:wIHHzd4F6 M3m4NlczKGh? Mn7QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCJQl2xJINmdGy|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBqdmO3YnH0[YQh\m:{IEeyJIhzeyCkeTDXV3QuOSCvZYToc4QtKEmFNUC9NE41PiEQvF2= MU[yOlM2PTV|Mh?=
human U937 cells MoXQR5l1d3SxeHnjxsBie3OjeR?= NEDx[GI1QCCq NGjoPGJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWQTN5IHPlcIx{KGW6cILld5NqdmdicEWzJI12fGGwdDDh[pRmeiB2ODDodpMh[nliU2LCJIF{e2G7IP-8kEBKSzVyPUGuNUDPxE1? MV[xPVcyPTNzOR?=

... Click to View More Cell Line Experimental Data

In vivo Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7 Luc and DU-145 Luc cells
  • Concentrations: 0 μg/mL - 0.692 μg/mL
  • Incubation Time: 96 hours
  • Method:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice with MCF-7 Luc or DU-145 Luc cells
  • Formulation: PBS
  • Dosages: 0.25 mg/mL
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 457.91
Formula

C23H23N3O5.HCl

CAS No. 119413-54-6
Storage powder
in solvent
Synonyms NSC609699, Nogitecan HCl, SKFS 104864A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03126916 Recruiting Childhood Ganglioneuroblastoma|Childhood Neuroblastoma|INRG Stage L2|INRG Stage M|INRG Stage MS|NMYC Gene Amplification|Recurrent Neuroblastoma Children''s Oncology Group|National Cancer Institute (NCI) May 9 2018 Phase 3
NCT02278510 Completed Malignant Glioma|WHO Grade III or IV Recurrent Glioma Michael Vogelbaum MD PhD|Infuseon Therapeutics Inc.|Case Comprehensive Cancer Center December 9 2014 Early Phase 1
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1
NCT03289910 Suspended Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) June 8 2018 Phase 2
NCT00158886 Terminated Carcinoma Renal Cell GlaxoSmithKline November 8 2001 Phase 1
NCT00186888 Active not recruiting Retinoblastoma|Retinal Neoplasm St. Jude Children''s Research Hospital|National Cancer Institute (NCI) April 7 2005 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • Answer:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Topotecan HCl | Topotecan HCl supplier | purchase Topotecan HCl | Topotecan HCl cost | Topotecan HCl manufacturer | order Topotecan HCl | Topotecan HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID